Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 80 lat
- •Potwierdzony rozpoznaniem raka prostaty
- •Wcześniejsze leczenie chemioterapią (taksan) i hormonalnym
- •Oczekiwana przeżywalność co najmniej 12 tygodni
- •Dobry ogólny stan zdrowia (ocena 0-1 wg skali ECOG)
- •Chęć i zdolność do podpisania zgody na udział w badaniu
✗ Disqualifies
- •Wcześniejsze leczenie podobnymi lekami (degradery receptora androgenowego)
- •Przerzuty nowotworu do mózgu
- •Poważne infekcje lub zaburzenia psychiczne
- •Plany przyjmowania innych leków przeciwnowotworowych podczas badania
- •Recent udział w innym eksperymentalnym leczeniu (w ciągu 4 tygodni)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- August 31, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Shanghai Jiaotong University School of Medicine, Renji Hospital
Shanghai, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.